PHARMACOKINETICS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH-FACTOR-I INDIALYSIS PATIENTS

Six maintenance hemodialysis (MHD), six continous ambulatory peritonea l dialysis (CAPD) and six normal adults underwent pharmacokinetic stud ies of insulin-like growth factor-1 (IGF-1). Each subject received two separate subcutaneous injections of recombinant human IGF-1 (rhIGF-1) (50 or 100 mu g/kg) in random order separated by 7 to 21 days. Two di fferent responses were observed. With the 50 mu g/kg dose, serum IGF-1 levels and the pharmacokinetic parameters were not different between the three groups. With the 100 mu g/kg dose, peak serum IGF-1 concentr ations were significantly greater in the MHD and CAPD patients than in normals. However, by 12 to 14 hours after injection, serum IGF-1 was not different in the three groups. Although the T-max, area under the curve and serum clearance of IGF-1 were similar in the three groups, t he half-life and volume of distribution of rhIGF-1 was significantly d ecreased in both MHD and CAPD patients. These data indicate that IGF-1 pharmacokinetics are abnormal in maintenance dialysis patients.